While the benefits of gastric bypass (GB) surgery in type 2 diabetes are well established, few studies have evaluated the long-term effects of GB in patients with type 1 diabetes ([@B1],[@B2]), and these studies demonstrate conflicting effects on glycemic control. This is clinically important given the increasing prevalence of obesity in patients with type 1 diabetes ([@B3]). We studied 10 severely obese women with confirmed type 1 diabetes, as previously described ([@B4]), and evaluated outcomes prior to GB and at 1 and 5 years following surgery. Mean age at GB was 39.6 ± 8.4 years, mean duration of type 1 diabetes 24.6 ± 10.1 years, and mean age at diagnosis 16.0 ± 8.3 years. Six subjects used continuous subcutaneous insulin infusion.

BMI decreased by 33% from baseline at 1 year postoperatively (from 43.5 ± 7.5 to 29.3 ± 5.4 kg/m^2^, *P* \< 0.0001) but increased by a mean of 15% (to 33.8 ± 7.5 kg/m^2^, *P* \< 0.01) from 1 to 5 years ([Table 1](#T1){ref-type="table"}). Compared with baseline, HbA~1c~ was unchanged at 1 year (baseline 8.1 ± 1.3% \[65 ± 14.2 mmol/mol\] to 1 year 8.3 ± 1.4% \[67 ± 15.3 mmol/mol\], *P* = 0.47). Interestingly, HbA~1c~ trended upward at 5 years postoperatively to 9.8 ± 1.9% (84 ± 20.8 mmol/mol, *P* = 0.15). Basal insulin requirements decreased from 53.0 ± 29.7 to 23.0 ± 15.6 units/day (*P* = 0.0005) at 1 year postoperatively but trended up from 1 to 5 years to 31.1 ± 22.8 units/day (*P* = 0.17). The trend held even when accounting for body weight. There was a robust correlation between change in insulin dose and weight (*r* = 0.66; *P* = 0.04).

###### 

Anthropometric and cardiometabolic risk factors and glycemic control at baseline (*n* = 10) and at 1 (*n* = 10) and 5 (*n* = 7) years following GB surgery

                                       Baseline       1 year         *P* value[†](#tblfn2){ref-type="table-fn"}     5 years         *P* value[‡](#tblfn3){ref-type="table-fn"}     *P* value[§](#tblfn4){ref-type="table-fn"}
  ------------------------------------ -------------- -------------- ---------------------------------------------- --------------- ---------------------------------------------- --------------------------------------------
  Weight (kg)                          121.9 ± 22.1   81.9 ± 15.8    \<0.0001[\*\*](#tblfn6){ref-type="table-fn"}   93.6 ± 21.0     \<0.0001[\*\*](#tblfn6){ref-type="table-fn"}   \<0.01[\*](#tblfn5){ref-type="table-fn"}
  BMI (kg/m^2^)                        43.5 ± 7.5     29.3 ± 5.4     \<0.0001[\*\*](#tblfn6){ref-type="table-fn"}   33.8 ± 7.5      \<0.0001[\*\*](#tblfn6){ref-type="table-fn"}   \<0.01[\*](#tblfn5){ref-type="table-fn"}
  HbA~1c~ (%)                          8.1 ± 1.3      8.3 ± 1.4      0.47                                           9.8 ± 1.9       0.15                                           0.26
  HbA~1c~ (mmol/mol)                   65 ± 14.2      67 ± 15.3      0.47                                           84 ± 20.8       0.15                                           0.26
  Basal insulin (units/day)            53.0 ± 29.7    23.0 ± 15.6    0.0005[\*\*](#tblfn6){ref-type="table-fn"}     31.1 ± 22.8     0.02[\*](#tblfn5){ref-type="table-fn"}         0.17
  Basal insulin (units/kg/day)         0.42 ± 0.19    0.27 ± 0.13    0.0005[\*\*](#tblfn6){ref-type="table-fn"}     0.37 ± 0.17     0.0021[\*](#tblfn5){ref-type="table-fn"}       0.174
  Insulin pump, *n* (%)                6 (60)         6 (60)                                                        5 (71)                                                         
  Multiple daily injections, *n* (%)   4 (40)         4 (40)                                                        2 (29)                                                         
  Systolic blood pressure (mmHg)       123.6 ± 8.3    112.6 ± 11.3   0.003[\*](#tblfn5){ref-type="table-fn"}        118.7 ± 14.1    0.45                                           0.19
  Diastolic blood pressure (mmHg)      72.8 ± 8.3     69.7 ± 4.2     0.32                                           72.4 ± 7.2      0.97                                           0.57
  HDL (g/dL)                           61.5 ± 18.4    63.0 ± 11.8    0.8                                            80.5 ± 16.7     0.04[\*](#tblfn5){ref-type="table-fn"}         0.004[\*](#tblfn5){ref-type="table-fn"}
  LDL (g/dL)                           102.3 ± 20.4   92.8 ± 20.5    0.41                                           91.5 ± 26.3     0.44                                           0.95
  Total cholesterol (g/dL)             185.4 ± 30.9   172.7 ± 24.2   0.59                                           195.3 ± 27.5    0.72                                           0.07
  Triglycerides (g/dL)                 112.8 ± 55.1   80.6 ± 43.6    0.004[\*](#tblfn5){ref-type="table-fn"}        111.2 ± 109.5   0.12                                           0.29
  Microalbumin (mg/L)                  62.2 ± 142     21.5 ± 26.7    0.34                                           14.2 ± 16.3     0.29                                           0.07

Data are presented as mean ± SD, unless otherwise noted.

1 year compared with baseline.

5 years compared with baseline.

5 years compared with 1 year.

Significant at *P* \< 0.05.

Significant at *P* \< 0.001.

Cardiometabolic risk factor assessment showed decreases in plasma triglycerides (28% decrease, *P =* 0.004) and systolic blood pressure (mean decrease of 11 ± 8.3 mmHg, *P* = 0.003) at 1 year; however, these decreases were not sustained at 5 years. There was no significant change in diastolic blood pressure, total cholesterol, or LDL. Interestingly, HDL increased by 22% from 1 to 5 years following GB surgery (*P* = 0.004). Despite limited data on diabetes-related complications, microalbuminuria tended to improve, though this was largely driven by one subject. One subject had severe nonproliferative diabetic retinopathy (NPDR) at baseline, which improved to moderate NPDR at 1-year follow-up; moderate NPDR was unchanged in two subjects 1 year postoperatively.

We conclude that GB does not improve long-term glycemic control in severely obese women with type 1 diabetes. However, GB reduced body weight and improved several cardiometabolic risk factors for up to 5 years following surgery. The lack of sustained effect of GB on glycemic control in individuals with type 1 diabetes is likely a consequence of their persistent absolute insulin requirement, resulting in periods of fasting hyperglycemia and increased variability of postprandial glucose excursions, as previously demonstrated in subjects with type 2 diabetes after GB ([@B5]). GB markedly alters patterns of early postprandial glycemia, contributing to a potential mismatch between nutrient absorption and prandial insulin timing.

Our study was limited by small sample size and single-sex cohort. Nevertheless, our evaluation of anthropometric, glycemic, and cardiometabolic outcomes at multiple time points following GB surgery in severely obese women with type 1 diabetes suggests that GB induces weight loss and improvement of some cardiovascular risk factors but does not improve long-term glycemic control in women with type 1 diabetes.
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